Search for Terms or Answers
The CLEAR study was a one-year, randomized, double-blind trial compared subcutaneous standard doses of secukinumab (anti-IL17) and ustekinumab (anti-IL12/23) in patients with moderate-severe plaque psoriasis.
Most Americans value the prescription products the drug industry produces, but they sure don't like the prices and want the federal government to take action, according to a new survey
Based on potentiallly off-label promotion of blockbuster drugs Aranesp and Enbrel, Amgen has agreed to a $71 million settlement with 48 states and the District of Columbia.
Tektonidou and coworkers have analyzed hospitalized serious infections (SIE) involving lupus patients over a 15 year period and show that SIE in SLE have increased substantially between 1996 and 2011, and in 2011 are 12 times higher than seen in patients without SLE.
Feldman and coworkers have analyzed US Medicaid claims data from 9,600 hydroxychloroquine and 3,829 new immunosuppressive new users with a diagnosis of SLE.
Regeneration of cartilage is the holy grail of osteoarthritis research.
Musculoskeletal ultrasound (US) was recently used in a longitudinal study Achilles enthesis of 146 patients with early spondyloarthritis (SpA). Usual measures of SpA activity included BASFI, BASRI-spine, BASDAI and Ankylosing Spondylitis Disease Activity Score (ASDAS).
Sleep disruption is a core feature of fibromyalgia. People with fibromyalgia exhibit sleep brain wave patterns often disrupted by brain waves that correspond to wakefulness.
Rheumatoid arthritis patients are often said to have no or a low risk of cancer.
Dr. Steven Katz describes how NIAMS sets priorities for investing congressionally-appropriated funds.
Dr. Marty Bergman (see prior article) writes to remind rheumatologists that the October 1 deadline is for the date of service. If you see the patient on September 30th, but don't bill it until October 4th, you need to use ICD-9 codes.
Smoking is a well-known inciting or exacerbating factor in many inflammatory diseases, including rheumatoid arthritis, juvenile arthritis, ankylosing spondylitis, Crohn's disease and ulcerative colitis.
Rituximab has been used for years with good efficacy, but with several safety concerns. Van Vollenhoven and colleagues have published the cumulative clinical trial safety experience of RTX wherein 3595 patients 1–20 (average - 4) courses over 11 years [14,816 patient-years (PY)].
A cross-sectional survey of 309 Brazilan rheumatologists was performed to assess their compliance with the 2012 ACR guidelines on gout.
Behcet's disease is difficult to treat and often has an over-reliance on corticosteroid use. Alemtuzumab (previously known as Campath-1H) has been studed in patients with Behcet's.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
